MNTA: That is partially my point: Why doesn't MNTA immediately expand their current M-118 trials with the assets they currently have? Or, would the cash drain be excessive given the entire pipeline cost? I view it as a positive dilemma, if M-118 works as hoped for. Perhaps they are waiting for data and/or other pipeline news such as M-Enox FDA pathway before making an election on the M-118 big picture.
"Illegitimacy is something we should talk about in terms of not having it."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.